NovaBay Pharmaceuticals, Inc. Selling, General and Administrative Expense of Revenue

Selling, General and Administrative Expense of Revenue of NBY for past 10 years: annual, quarterly and twelve month trailing (TTM) including Selling, General and Administrative Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Selling, General and Administrative Expense of Revenue for the quarter ending June 30, 2022 was 120.26% (a -18.3% decrease compared to previous quarter)
  • Year-over-year quarterly Selling, General and Administrative Expense of Revenue decreased by -38.98%
  • Annual Selling, General and Administrative Expense of Revenue for 2021 was 171.75% (a 40.95% increase from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2020 was 121.85% (a -42.88% decrease from previous year)
  • Annual Selling, General and Administrative Expense of Revenue for 2019 was 213.32% (a 43.32% increase from previous year)
  • Twelve month Selling, General and Administrative Expense of Revenue ending June 30, 2022 was 155.3% (a -7.19% decrease compared to previous quarter)
  • Twelve month trailing Selling, General and Administrative Expense of Revenue decreased by -5.84% year-over-year
Trailing Selling, General and Administrative Expense of Revenue for the last four month:
30 Jun '22 31 Mar '22 31 Dec '21 30 Sep '21
155.3% 167.33% 171.75% 164.93%
Visit stockrow.com/NBY for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Selling, General and Administrative Expense of Revenue of NovaBay Pharmaceuticals, Inc.

Most recent Selling, General and Administrative Expense of Revenueof NBY including historical data for past 10 years.

Interactive Chart of Selling, General and Administrative Expense of Revenue of NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals, Inc. Selling, General and Administrative Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 120.26% 147.2%
2021 174.67% 197.07% 157.38% 158.66% 171.75%
2020 148.15% 164.56% 72.79% 149.95% 121.85%
2019 195.48% 178.14% 152.77% 344.47% 213.32%
2018 129.32% 145.58% 155.23% 170.27% 148.84%
2017 76.01% 137.06% 123.99% 184.49% 122.58%
2016 126.15% 143.37% 155.69% 280.74% 160.07%
2015 372.35% 393.0% 422.32% 644.61% 422.94%
2014 553.36% 1257.24% 1343.9% 593.06% 757.97%
2013 237.25% 138.76% 241.16% 152.94% 182.34%
2012 164.27% 33.88% 157.06% 116.74% 85.98%
2011 121.87% 39.57% 49.27%

Business Profile of NovaBay Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology